Extracellular Vesicle‐Mediated Regulation of H3C14 Contributes to Gemcitabine Resistance in Bladder Cancer
Open Access
- 29 October 2025
- journal article
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 14 (11) , e70179
Abstract
Extracellular vesicles (EVs) are critical mediators of intercellular communication within the tumour microenvironment and play a significant role in drug resistance. We aimed to investigate the mechanisms underlying gemcitabine (GCB) resistance in bladder cancer. GCB‐resistant bladder cancer cells exhibited dysregulation of nucleoside‐metabolizing enzymes and transporters. Characterization of EV subpopulations derived from GCB‐resistant cells revealed their ability to transfer drug‐resistant phenotypes to naïve cancer cells by modulating intracellular levels of nucleoside metabolic proteins and transporters. Proteomic and transcriptomic analyses identified the histone protein H3.2 and its corresponding transcript, H3C14, as key regulators in the transmission of GCB resistance. Notably, H3C14 overexpression in resistant cells restored GCB sensitivity, whereas its knockdown induced GCB resistance. Rab27A‐mediated biogenesis and secretion emerged as a crucial mechanism regulating EV release and H3C14 excretion in GCB‐resistant cells. A specific EV subpopulation enriched in CD147 and LAMB1—referred to as Excretion EVs—carried H3.2 (H3C14) but did not induce GCB resistance in recipient cells, suggesting their primary role in eliminating proteins associated with tumour progression and drug resistance. These findings highlight the role of EV‐mediated H3C14 excretion in regulating GCB resistance and suggest potential therapeutic strategies targeting EV pathways to overcome drug resistance in bladder cancer.Keywords
Funding Information
- National Science and Technology Council (MOST 109‐2320‐B‐016‐007, MOST 110‐2314‐B‐016‐064, MOST 111‐2320‐B‐016‐008‐MY3, MOST109‐2314‐B‐016‐038, NSTC 114‐2320‐B‐016‐007)
- National Defense Medical Center (MND‐MAB‐D‐111110, MND‐MAB‐D‐111135, MND‐MAB‐D‐112096, MND‐MAB‐D‐112152, MND‐MAB‐E‐114100, MND‐MAB‐E‐114161, MNE‐MAB‐E‐113056, MNE‐MAB‐E‐113182)
- Tri-Service General Hospital (TSGH‐114‐248, TSGH‐E‐111221, TSGH‐E‐112221, TSGH‐E‐113246)
This publication has 104 references indexed in Scilit:
- Expression Patterns and Post-translational Modifications Associated with Mammalian Histone H3 VariantsJournal of Biological Chemistry, 2006
- Histone structure and nucleosome stabilityExpert Review of Proteomics, 2005
- Origin of multifocal carcinomas of the bladder and upper urinary tract: Molecular analysis and clinical implicationsInternational Journal of Urology, 2005
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Histone variants: deviants?Genes & Development, 2005
- Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populationsBlood, 2005
- SEVERE NEUROTOXICITY, OTOTOXICITY AND NEPHROTOXICITY FOLLOWING HIGH-DOSE CISPLATIN AND AMIFOSTINEPediatric Hematology and Oncology, 2005
- Cytotoxic activity of 2′,2′-difluorodeoxycytidine, 5-aza-2′-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase geneBiochemical and Biophysical Research Communications, 2002
- Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)Drug Resistance Updates, 2002
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyJournal of Clinical Oncology, 2000